Literature DB >> 3224534

Pharmacokinetics of thiopental in the asphyxiated neonate.

D C Garg1, R N Goldberg, R B Woo-Ming, D J Weidler.   

Abstract

The pharmacokinetic properties of thiopental were studied in 10 asphyxiated neonates (mean +/- SE; birth weight, 3,244 +/- 212 g; gestational age, 40 +/- 1 weeks) as part of a randomized, controlled trial which tested the ability of barbiturate therapy to decrease central nervous system damage secondary to perinatal asphyxia. Therapy was begun at a mean age of 2.3 h in all and was initially given as a loading dose of 15 mg/kg over 30 min followed by a constant infusion. The mean steady-state thiopental concentration was 13.4 +/- 3.7 micrograms/ml (mean +/- SD) and the average time to reach steady state was 7 +/- 5 h. Mean elimination half-life, plasma clearance and volume of distribution for thiopental were 39 h (range 26-70), 66 ml/(h x kg) (range 31-172), and 3.6 liters/kg (range 1.1-6.7), respectively. Arterial blood pressure support was required in 8 of 10 patients. While it appears feasible to give thiopental to the asphyxiated neonate at the reported infusion rates, the risk-benefit ratio is increased by the frequent associated hypotension and need for pharmacologic blood pressure support.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3224534     DOI: 10.1159/000457691

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  3 in total

1.  Neonatal pharmacology: extensive interindividual variability despite limited size.

Authors:  Cuneyt Tayman; Maisa Rayyan; Karel Allegaert
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

Review 2.  Pharmacodynamics and pharmacokinetics of thiopental.

Authors:  H Russo; F Bressolle
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

3.  Early Postnatal Seizures in a Neonate with Wolf-Hirschhorn Syndrome.

Authors:  Hayato Go; Kentaro Haneda; Hajime Maeda; Kei Ogasawara; Takashi Imamura; Nobuo Momoi; Mitsuaki Hosoya
Journal:  AJP Rep       Date:  2016-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.